Biologics use by rheumatoid arthritis patients was associated with a 25% reduction in the risk of premature death, compared to patients without exposure to biologics, based on data from a population-based study of more than 4,000 patients. Dr. Diane Lacaille of the Arthritis Research Center of Canada discusses the results at the American College of Rheumatology’s annual meeting.
Do biologics cut mortality in rheumatoid arthritis?
This content is restricted to CANRAD Network members. If you are an existing member, please login.
Biologics use by rheumatoid arthritis patients was associated with a 25% reduction in the risk of premature death, compared to patients without exposure to biologics, based on data from a population-based study of more than 4,000 patients. Dr. Diane Lacaille of the Arthritis Research Center of Canada discusses the results at the American College of Rheumatology’s annual meeting.
Biologics use by rheumatoid arthritis patients was associated with a 25% reduction in the risk of premature death, compared to patients without exposure to biologics, based on data from a population-based study of more than 4,000 patients. Dr. Diane Lacaille of the Arthritis Research Center of Canada discusses the results at the American College of Rheumatology’s annual meeting.